DocumentsDate added
Research article
Tandon Anupama1,*,Srivastava Dhiraj Kumar2,Sharma Pradeep3,Sarawat Neeraj4,Pandey AK5,Shukla Dipendra4
Affiliation:-
1Associate Professor, 4Post Graduate Student, Department of ophthalmology, UP Rural Institute of medical sciences and research , Saifai Etawah (UP)
2Assistant Professor, Department of Community Medicine,3Associate Professor, Department of Biochemistry, UP Rural Institute of Medical Sciences & Research, Saifai, Etawah(UP),India
5Assistant Professor,Department of Psychiatry, UP Rural Institute of Medical Sciences & Research, Saifai, Etawah(UP),India
The name of the department(s) and institution(s) to which the work should be attributed:
UP Rural Institute of Medical Sciences & Research, Saifai, Etawah(UP),India
*To whom it corresponds:-
Dr. Anupama Tandon.
Associate Professor,
Dept of Ophthmology,
UP Rural Institute of Medical Sciences & Research, Saifai, Etawah(UP) 20613,India
Contact No: 09917661687.
Abstract
Aims: The main was to analyse trends of traumatic cataract in rural areas and to evaluate the results of PCIOL Implantation in terms of final visual outcome, considering also factors affecting its outcome; various intraoperative and postoperative complications.
Material and Methods:
Study Design: Interventional, Consecutive, Non comparative, Case series.
Methodology: 50 patients of traumatic cataract who came to OPD between September 2013 to April 2014 of our institute with a minimum followup of 4 months were included in the study. Complete history; diagnostic evaluation including special investigations were done in each visit. Surgical protocol was decided and functional success in terms of best corrected visual acuity was noted.
Results: 50 cases of traumatic cataract with mean age of 24 years, male preponderance of 4 times and vision with accurate projection of rays were included. In these cases penetrating trauma with wooden stick was the most common cause (75% cases).the duration of cataract varied between 24 hours to 10 years. Most common associated ocular pathology was sealed tear in 98% cases. Ring application for IOFB localisation and electromagnets were required for its removal. Most common hinderance in regaining vision was pigment dispersion in early cases (60%). Still ECCE with PCIOL remains the most common modality of treatment. The best results in final visual acuity were only possible when cataract surgery and treatment was done as soon as possible. Final visual outcome were best in patients aged 16 & above.
Conclusion: The present study hereby conclude that clear relationship could be established between duration of cataract and final visual outcome but no clear relationship was seen between presurgical visual acuity and final visual outcome. Patients presented earlier showed better visual gains.
Keywords: BCVA best corrected visual acuity; IOL intraocular lenses; IOFB intraocular foreign body; PCO posterior capsular evaluation; ECCE extra capsular cataract evaluation.
REFERENCES
1.Gelfend Y,Pikkel J .Prognostic factors and surgical results in traumatic cataract. Harefauh, 1997;132 (1):p18-21.
2.Bowman RJ, Yorston D.Primary IOL implantation in penetrating lens trauma in Africa. Ophthalmology, 1998;105 (9):p1770-4.
3.Bhatia LM, Panda A, Sood NN. Management of Traumatic cataract. Ind. J .Ophthal.1982; 31:290 -91.
4.Blum M, Tetz R.Treatment of Traumatic cataract.J Cataract Refractive surg;1996; 22(3):343-346.
5.Chiqet C, Zech JC, Gain P. Visual Outcome and Prognostic factors after magnetic extraction of posterior segment Foreign Body in 40 cases. Br.J.Ophthalmol 1998,; 82 (7):801-6.
6.Dhir S.P., Mohan K.,Munjal VP. Perforating Ocular Injuries with retained IOFB.Ind. J. Ophthalmol 1984 Sept 32:289-92.
7.Tetz M, Blum M, Voleker HE. Traumatic cataracts -surgical methods and results in 106 patients. Ophthalmology, 1993;90 (4):360-3.
8.Chan TK, Mackintosh G. Primary PCIOL implantation in penetrating ocular trauma. Int .Ophthalmol, 1993;17(3): 137 -81.
9.Daljeet Singh Verma. Active vision therapy for pseudophakia ambylopia. J.Cataract Refract Surg.,1997 ; 23( 7 ) : 1089-94.
10.Anwar M, Bleik JH. PCIOL for primary repair of traumatic cataract in children.J. Paediatr Ophthalmol strabismus,1994; 31 ( 3 ): 157-61.
11.Goldberg M F. Management of Posterior Segment FB. J. State Med. Association, 1970; (11):149-53.
12.Brady KM ,Hiles DA. Cataract Surgery and IOL implantation in children.Am J .Ophthalmol,1995;120 (1) :105-7.
13.Basti S, Ravishankar U, Gupta S. Results of a prospective evaluation of three methods of management of pediatric cataracts.Ophthalmology. 1996;103:713–20.
14.Stark WJ, Taylor HR, Michels RG, et al. Management of congenital cataracts. Ophthalmology,1983; 9:157-160.
15.Hiles DA, Biglan AW. Surgery of traumatic cataract. Int.ophthalmol.Clin.,1997:17:147-56.
16.Koenig SB, Schultz RD. Pseudophakia for traumatic cataract in children. Ophthalmology, 1993; 100(8):1218-24.
17.Krishnamacharya M, Rathi V. Management of traumatic cataract in children.J. Cat.Refract Surgery,1997;23: 681-7.
Source of support: None
Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Article citation:
Tandon Anupama,Srivastava Dhiraj Kumar,Sharma Pradeep,Sarawat Neeraj,Pandey AK,Shukla Dipendra. Traumatic cataract and its management in a tertiary care institute in rural area of Central Uttar Pradesh,India. J Pharm Biomed Sci 2014;04(05):404-409. Available at www.jpbms.info.
Copyright © 2014 Tandon Anupama,Srivastava Dhiraj Kumar,Sharma Pradeep,Sarawat Neeraj,Pandey AK,Shukla Dipendra.This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Case report
Jasheena Singh1,Shruti Gupta2,*,Tejveer Singh3, Nidhi Mathur4,Priya Gupta2
Affiliation:-
1Professor and Head, Department of Pedodontics, Maharana Pratap College of Dentistry & Research Centre, Gwalior, India
2Senior Lecturer, Department of Oral Pathology, Luxmi Bai Institute of Dental Sciences & Hospital, Patiala, India
3Senior Lecturer, Department of Oral Surgery, Luxmi Bai Institute of Dental Sciences & Hospital, Patiala, India
4Professor and Head, Department of Pathology, Luxmi Bai Institute of Dental Sciences & Hospital, Patiala, India
The name of the department(s) and institution(s) to which the work should be attributed:
Department of Pedodontics, Maharana Pratap College of Dentistry & Research Centre, Gwalior, India
Department of Oral Pathology, Luxmi Bai Institute of Dental Sciences & Hospital, Patiala, India
Abstract
Lesions on tongue include a diverse group of developmental, reactive, neoplastic lesions and various systemic pathologies with oral manifestations. They often present diagnostic challenges because they mimic various groups of pathologic processes and thus necessitating the correlation of clinical and histopathological findings for accurate diagnosis. Thus, here we present a case of 14 year old male with growth on tongue along with emphasis on the differential diagnosis of tongue lesions.
Keywords: Fibroepithelial hyperplasia, Irritational fibroma, reactive.
*To whom it corresponds:-
Dr. Shruti Gupta.
H.No. 166, Old P.L.A Sector, Hisar, Haryana-125001,India
Contact no:+91-9465288400
Article citation:
Singh J, Gupta S, Singh T, Mathur N, Gupta P. Tongue Lesions: A Diagnostic Challenge. J Pharm Biomed Sci 2014;04(05):459-462. Available at www.jpbms.info.
REFERENCES
1.Reamy BV, Derby R, Bunt CW. Common tongue conditions in primary care. Am Fam Physician 2010;81:627-34.
2.Laskin DM, Giglio JA, Rippert ET. Differential diagnosis of tongue lesion. Quintessence Int 2003;34:331-42.
3.Prasanna JS, Sehrawat S. Fibroepithelial hyperplasia: rare, selflimiting condition- two case reports. J Adv Oral Research 2011;2:63-70.
4.Regezi JA, Sciubba JJ, Jordan RCK. Oral pathology: clinical pathologic correlations.6th ed. St. Louis, Missouri, Saunders;2012.
5.Shafer, Hine, Levy. Shafer’s textbook of oral pathology. 6th ed. India: Elsevier;2009.
6.Neville BW, Damm DD, Allen CM, Bouquot JE. Oral and Maxillofacial Pathology. 3rd ed. Missouri: Saunders; 2009.
7.Tyldesley WR. Inflammatory overgrowths and neoplasms. Br Dent J 1974;136:111-6.
8.McNally MA, Langlais RP. Conditions peculiar to the tongue. Dermatol Clin 1996; 14:257-72.
9.Pedron GI, Ramalho KM, Moreira LA, de Freitas PM. Association of two lasers in the treatment of traumatic fibroma: excision with Nd: YAP laser and photobiomodulation using InGaAIP: a case report. J Oral Laser Applications 2009;9:49-53.
Copyright © 2014 Singh J, Gupta S, Singh T, Mathur N, Gupta P. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Source of support: None
Competing interest /Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Research article
Lakshminarasimhaiah1,*, S. Alexander2
Affiliation:-
1Prasad Institute of Pharmaceutical Sciences, Jangaon-506167, Warangal District, Andhra Pradesh, India.
2J.S.S College of Pharmacy, Rocklands, Post Box No:20, Ootacamund-643 001, Tamil Nadu, India
The name of the department(s) and institution(s) to which the work should be attributed:
Prasad Institute of Pharmaceutical Sciences, Jangaon-506167, Warangal District, Andhra Pradesh, India
J.S.S College of Pharmacy, Rocklands, Post Box No: 20, Ootacamund-643 001, Tamil Nadu, India
*To whom it corresponds:-
Lakshminarasimhaiah;
Prasad Institute of Pharmaceutical Sciences, Jangaon-506167, Warangal District, Andhra Pradesh, India
Abstract:
In the present investigation a series of pyrazole derivatives were synthesized by condensation of 8-acetyl, 7-hydroxy, 4-methyl coumarin (I) with substituted benzaldehyde to form chalkone (II). The obtained chalkone was treated with phenyl hydrazine to form pyrazole derivatives(IIIa-h). The synthesized compounds were characterized by IR, NMR, Mass spectra and Elemental analysis. New compounds were screened for their antimicrobial studies against S. aureus, B. subtilis, E. coli and P. aeruginosa. The results revealed that compound IIIe has ortho chlorophenyl substituent showed significant antibacterial activity against all tested microorganisms as compared to the standard drug Ceftriaxone. Keywords: Antimicrobial activity; chalkone; pyrazole; substituted benzaldehyde; spectral data.
REFERENCES
1.Catterall R. D. Fatal reaction to phenylbutazone in a patient with Reiter's Disease. British Journal of Veneral Disease. 1968; 44:151-153.
2.Farber D and Liel E. V. Phenylbutazon-Vergiftungim Kindesalter. Tagl Prax. 1968; 9:231-233.
3.Mariappan G, Saha B. P, Sutharson L and Haldar A. Synthesis and bioactivity evaluation of pyrazolone derivatives. Indian Journal of Chemistry. 2010;49B: 1671-1674.
4.Prasanna raja P, Riyazulah M.S and Siva kumar V. Synthesis and biological evaluation of some chalcone derivatives. International Journal of ChemTech Research. 2010;2(4):1998-2004.
5.Essam Mohamed Sharshira and Nagwa Mohamed Mahrous Hamada. Synthesis and antimicrobial evaluation of some pyrazole derivatives. Molecules. 2012; 17:4962-4971.
6.Vibhute Y.B. and Basser M.A., Synthesis and activity of a new series of Chalcones as antibacterial agents. Indian Journal of Chemistry. 2003; 42B:202-205.
7.Bhat B. A, Dhar K. L, Saxena A. K, Shanmugavel M. Synthesis and biological evaluation of Chalcones and their derived Pyrazoles as potential cytotoxic agents. Bioorganic and Medicinal Chemistry. 2005;15(3): 3177-3180.
8.Kalirajan R, Palanivelu M, Rajamanickam V, Vinothapooshan G and Anandarajagopal K. Synthesis and biological evaluation of some Chalcone derivatives. International Journal of Chemical Science. 2007;5(1):73-80.
9.Ausra Voskiene, Vytautas Mickevicius, and Gema Mikulskiene. Synthesis and structural characterization of products condensation 4-carboxy-1-(4-styrylcarbonylphenyl)-2-pyrrolidinones with hydrazines. ARKIVOC. 2007; (xv),303-314.
10.Seranthimata Samshuddin , Badiadka Narayana, Balladka Kunhanna Sarojini, Rajagopalan Srinivasan, Vinayachandra and Chandrashekar K. R. Synthesis, characterization and biological evaluation of some pyrazoles derived from α, β-dibromo 4, 4'-difluoro chalcone. Der Pharma Chemica. 2012;4(2):587-592.
11.Kavitha N. V, Kalpana Divekar, Brahmani Priyadarshini, Gajanan S and Manjunath M. Synthesis and antimicrobial activities of some new pyrazole derivatives. Der Pharma Chemica. 2011;3(4):55-62.
12.Mohamed M. F, Mohamed M. S, Shouman S. A, Fathi M. M and Abdelhamid I. A. Synthesis and biological evaluation of a novel series of chalcones incorporated pyrazole moiety as anticancer and antimicrobial agents. Applied Biochemical Biotechnology. 2012;168(5):1153-1162.
13.Byeongno Lee, Philjun Kang, Kyu Hyung Lee, Jaeheung Cho, Wonwoo Nam, Won Koo Lee and Nam Hwi Hur. Solid-state and solvent-free synthesis of azines, pyrazoles, and pyridazinones using solid hydrazine. Tetrahedron Letters. 2013;54:1384–1388.
14.Corradi A, Leonelli C, Rizzuti A, Rosa R, Veronesi P, Grandi R, Baldassari S, Villa C. New “Green” Approaches to the Synthesis of Pyrazole Derivatives. Molecules. 2007;12(7):1482-1495.
15.Mackie and Mc. Cartney. Practical Medicinal Microbiology 13th edition, Chuchill Livingstone. Edinburgh; 1989:87.
Article citation:
Lakshminarasimhaiah, S. Alexander. Synthesis and antimicrobial activity of new heterocyclic compounds. J Pharm Biomed Sci. 2014;04(05):422-426. Available at www.jpbms.info.
Source of support: None
Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Review article
Nagi Idris1,*,Faraj E Homry Mohamed2,Manzoor A Thokar3
Affiliation:-
1 Faculty of Pharmacy,Omer Al Mukhtar University, Albeda, Libya
2 Faculty of Medicine Omar Al Mukhtar University, Albeida, Libya
3Professor & Head Microbiology, Faculty of Pharmacy Omer Al Mukhtar University, Albeda, Libya
The name of the department(s) and institution(s) to which the work should be attributed:
Omer Al Mukhtar University, Albeda, Libya
*To whom it corresponds:-
Dr Manzoor A Thokar.
Professor & Head Microbiology, Faculty of Pharmacy , Omer Al Mukhtar University, Albeda, Libya
Contact number:+218 944828775
Abstract:
Our main antibiotic weaponry such as 3rdgeneration cephalosporin’s (ceftazidime, ceftriaxone, cefperazone, cefotaxime to name a few) and carbapenams (imipenum, merpenam,doripenam etc) are at a stage of extinction due to the onslaught of Esbl(Extended spectram β lactamase & Mbl (metallo ß lactamase) enzyme inactivation’s by way of hydrolysing their beta-lactam ring &resistance originally remaining confined to few germs started disseminating to others irrespective of gram positive, gram negative, cocci or bacilli nature and unfortunately resistance was extended to other antibiotic classes also.
Outbreak producing pathogens such as MRSA, E.coli, Klebsiella, Pseudomonas and VRE, are already causing global havoc with their resistance venom. There is every danger that VISA/GISA (Vancomycin & Glycopeptide intermediate resistant Staphylococcus aureus) may be a full-fledged future VRS (vancomycin resistant Staphylococcus aureus) entity.
Scientific innovations get modified from time to time & so get interpretations. What is logic today may not be applicable tomorrow. We have to change as per the changing times & keep abreast with latest developments & incorporate need based surveillance and research tools like Esbl & Mbl technologies in our systems otherwise wrongs would continue to happen
Global proliferation of antibiotic resistance to microbes is attributed to injudicious use of antibiotics at global, national & local levels. Antibiotic usage has to be rationalized for choice, dose & duration in prophylactic, empirical & therapeutic treatment modalities & antibiotic policies need to be formulated on evidence based medicine.
Keywords: Mbl; Esbl; 3rd G cephalosporine; Carbapenam.
REFERENCES
1.Pier GB, Ramphal R. Pseudomonas aeruginosa. In: Mandell GL, Benett JE, Dolin R, editors. Principles and practice of infectious disease 6th edition. New York: Churchill Livingstone; 2005.p 2587-2608. Elsevier, Philadelphia.
2.Govan JR. Pseudomonas, Sternotrophomonas, Burkholderia. In: Colle JG, Fraser AG, Marnion BP, Simmons A, editors. Mackie and McCartney Practical Medical Microbiology 14th ed. Churchill Livingstone; 1996.p. 413-424.
3.Wiblin RT. Nosocomial Pneumonia. In Wenzel RP, editor. Prevention and control of nosocomial infections 3rd ed. Williams and Wilkins; 1997.p. 807-19.
4.Pollack M. Pseudomonas aeruginosa. In Mandell GL, Benett JE, Dolin R, editors. Principles and practice of infectious disease 4th edition. New York: Churchill Livingstone; 1995.p.1980-2003.
5.Kluytmans J. Surgical infections including burns. In: Wenzel R.P., editor. Prevention and Control of Nosocomial Infections (3rd ed.) Williams and Wilkins; Pennsylvania: 1997. pp. 841–65.
6.Fergie JE, Shema SJ, Lott L, Crawford R, Patrick CC. Pseudomonas aeruginosa bacteremia in immunocompromised children: analysis of factors associated with a poor outcome. Clin Infect Dis.1994;18:390-4.
7.Bergen GA, Shelhamer JH. Pulmonary infiltrates in cancer patients. New approaches to an old problem. Infect Dis Clin North Am. 1996 Jun; 10:297-326.
8.Latham R and Shaftner W. Hospital epidemiology. In: Encylopedia of Microbiology Vol 2 Chief ed. Lederberg 471 Acad Press London 1992.p 471.
9.Szabó D, Szentandrássy J, Juhász Z, Katona K, Nagy K, Rókusz L.Imported PER-1 producing Pseudomonas aeruginosa, PER-1 producing Acinetobacter baumanii and VIM-2-producing Pseudomonas aeruginosa strains in Hungary. Ann Clin Microbiol Antimicrob. 2008 May 30;7:12. doi: 10.1186/1476-0711-7-12.
10.Forbes BA, Sham DF, Weissfeld AS, editors. In Bailey and Scott Diagnostic Microbiology.12th edition Mosby 2007; p. 172-186.
11.Nathisuwan S, Burgess DS, Lewis 11 JS. ESBLs: Epidemiology, detection and treatment. Pharmacotherapy. 2001; 21(8):920-928.
12.Varaiya A, Kulkarni M, Bhalekar P, Dogra J. Incidence of metallo-beta-lactamase producing Pseudomonas aeruginosa in diabetes and cancer patients.Indian J Patho Microbiol.2008Apr-Jun;51(2):200-3.
13.Nordmann P, Poirel L. Emerging carbapenemases in gram negative aerobes. Clin Microbiol Infect.2002 Jun;8(6):321-331.
14.Walsh TR, Toleman MA, Poirel L, Nordman P. Metallo ß–lactamase: the quiet before storm?Clin Microbiol Rev 2005;18:306-25.
15.Hemlatha V, Sekar U, Kamat V. Detection of metallo-beta-lactamase producing Pseudomonas aeruginosa in hospitalized patients. Indian J Med Microbiol.2005 Aug;122:148-152.
16.Franklin C, Liolios L, Peleg AY.Phenotypic detection of carbapenem-susceptible metallo-beta-lactamase-producing gram-negative bacilli in the clinical laboratory.J Clin Microbiol. 2006 Sep;44(9):3139-44.
17.Mendiratta DK, Deotale V, Narang P.Metallo-beta-lactamase producing Pseudomonas aeruginosa in a hospital from a rural area.Indian J Med Res. 2005 May;121(5):701-3.
18.Andrade SS, Picao RC, Campana EH, Nicoletti AG, Pignatari ACC, Gales AC. Influence of disk preparation on detection of metallo-ß-lactamase producing isolates isolates by combined disc assay. J Clin Microbiol. 2007 Jun;45(6):2058-60. Epub 2007 Apr 4.
19.Pitout J, Gregson DB, Poirel L, MC Clure JA, Le P, Church DL. Detection of Pseudomonas aeruginosa producing metallo-beta-lactamases in a large centralized laboratory. J Clin Microbiol. 2005 Jul;43(7):3129-35.
20.Yan JJ, Wu JJ, Tsai SH, Chaung CL. Comparison of double disk, combined-diskand E-test methods for detecting metallo-beta-lactamases in gram negative bacilli. Diagn Microbiol Infect Dis. 2004 May;49(1):5-11.
21.Pitout JD, Chow BL, Gregson DB, Laupland KB, El Sayed S, Chruch DL. Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa in the Calgary Health Region: emergence of VIM-2-producing isolates. J Clin Microbiol. 2007 Feb;45(2):294-8. Epub 2006 Nov 22.
22.Marra AR, Pereira CA, AC, Menezes LC, Cal RG, de Souza JM, Edmond MB, Faro C, Wey SB.Blood stream infections with metallo-beta-lactamase-producing Pseudomonas aeruginosa: epidemiology, microbiology, and clinical outcomes.Antimicrob Agents Chemother. 2006 Jan;50(1):388-90.
23.Tripathi KD, Essentials of Medical Pharmacology, Antimicrobial Drugs: General Consideration, Jaypee brother’s Medical publishers (P) Ltd: New Delhi,2003;5th edition: 627-640.
24.Madoff LC, Kasper DL. Introduction to Infectious diseases: Host-Parasite interactions. In Braunwald E, Fauci AS, Kasper DL, Hauser SL, Lango DL,Jameson JL,editors.Priniciples of internal Medicine.15th edition.MC Graw Hill 2001;763-67.
25.Medeiros AA. Evolution and dissemination of β–lactamases accelerated by generations of β–lactam antibiotics. Clin Infect Dis 1997; 24 suppl 1:519-45.
26.Bush K. New beta-lactamases in Gram negative bacteria; diversity and impact on selection of antimicrobial therapy. Clinical Infect Dis 2001;32:1085-9.
27.Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for beta-lactamases and its correlation with molecular structure.Antimicrob Agents Chemother. 1995 Jun;39(6):1211-33.
28.Paterson DL, Bonomo RA. Extended spectrum ß–lactamases: A clinical update. Clin Microbiol Rev. 2005; 18: 657-86.
29.Lee K, Lim YS, Yong D, Yum JH, Chong Y.Evaluation of the Hodge test and the imipenem-EDTA double-disk synergy test for differentiating metallo-beta-lactamase-producing isolates of Pseudomonas spp. and Acinetobacter spp.J Clin Microbiol. 2003 Oct;41(10):4623-9.
30.Jacoby GA, Munoz-Price LS.The new beta-lactamases.N Engl J Med. 2005 Jan 27;352(4):380-91.
31.Lee, K., J. B. Lim, J. H. Yum, D. Yong, Y. Chong, J. M. Kim, and D. M. Livermore. 2002. blaVIM-2 cassette-containing novel integrons in metallo-β-lactamase-producing Pseudomonas aeruginosa and Pseudomonas putida isolates disseminated in a Korean hospital. Antimicrob. Agents Chemother. 46:1053-1058.
32.Watanabe M, Iyobe S, Inoue M and Mitsuhashi S. Transferable imipenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother.1991;35:147-151.
33.Osano E, Arakawa Y, Wacharotayankun R, Ohta M, Horri T, Ito H, Yooshimura Fand Kato N. Molecular characterization of an enterobacterial metallo-beta-lactamase found in a clinical isolate of Serratia masrcescens that shows imipenem resistance. Antimicrob Agents Chemother.1994;38:71-78.
34.Laurelli L, Riccio ML, Mazzariol, Cornaglia G, Amicosante G, Fontana R and Rossolini GM. Cloning and characterization of blaVIM, a new integron-borne metallo-ß-lactamase gene from a Pseudomonas aeruginosa clinical isolate. Antimicrob Agents Chemother. 1999;43:1584-90.
35.Tsakris A, Pournaras S, Neil W, Marie-France J, Babini GS, John D, David ML. Outbreak of infections caused by P. aeruginosa producing VIM-1 cabbapenemase in Greece. J Clin Microbiol. 2000;38:1290-92.
36.Castanheira, Toleman MA, Jones RN, Schmidt FJ, Walsh TR. Molecular characterization of a ß-lactamase gene blaGIM-1, encoding a new subclass of metallo-ß-lactamase. Antimicrob. Agents Chemother.2004;48:4654-4661.
37.Navaneeth BV, Sridaran D, Sahay D, Belwadi MR. A preliminary study on metallo beta-lactamase producing Pseudomonas aeruginosa in hospitalized patients. Indian J Med Res 2000;116:264-7.
38.Migliavacca R, Docquier JD, Mognaioli C, Amicosante G, Daturi R, Lee K, Maria R, Pagani L. Simple microdilution test for detecting metallo-beta-lactamase production in Pseudomonas aeruginosa. J Clin.Microbiol.2002;40:4388-90.
39.Walsh TR, Bolmstrom A, Qwarnstrom A, Gales A. Evaluation of a new E-test for detecting metallo-beta-lactamases in routine clinical testing. J Clin. Microbiol. 2002; 40: 2755-2759.
40.Hirakata Y, Izumikwa K, Matsuda J, Nakano M, Mine M et al. Clinical and bacteriological characteristics of IMP-type metallo-beta-lactamase producing Pseudomonas aeruginosa. Clin Infect Dis. 2003; 37:26-32.
41.Gladstone P, Rajendran P, Brahmadathan KN. Incidence of carbapenem resistant non fermenting gram negative bacilli from patients with respiratory infections in intensive care units. Indian J Med Microbiol. 2005;23:189-191.
42.Jesudason MV, Kandathil AJ, Balaji V. Comparison of two methods to detect carbapenemase and metallo-ß-lactamase production in clinical isolates. Indian J Med Res. 2005; 121: 780
43.Chacko B, Varaiya A, Dedhia B. Imipenem resistant metallo-beta-lactamase producing Pseudomonas aeruginosa. Indian J Med Microbiol. 2008; 26:398-41.
44.Behera B, Mathur P, Das A, Kapil A, Sharma V. An evaluation of four different phenotypic techniques for detection of metallo-beta-lactamase producing Pseudomonas aeruginosa. Indian J Med Microbiol. 2008; 26: 233-37.
45.Clinical and Laboratory Standards Institute. 2006. M2-A9. Performance standards for antimicrobial disk susceptibility tests; approved standard, 9th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
46.Lee K, Lim YS, Yong D, Yum JH, Chong Y. Evaluation of the Hodge test and the imipenem-EDTA double-disk synergy test for differentiating metallo-beta-lactamase-producing isolates of Pseudomonas spp. and Acinetobacter spp. J Clin Microbiol. 2003 Oct;41(10):4623-9.
47.Karthikeyan K Kumarasamy, Mark A Toleman, Timothy R Walsh, Jay Bagaria, Fafh ana Butt, Ravikumar Balakrishnan et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 2010;10: 597–602.
48.Allaaeddin El Salabi, Mark A. Toleman,Janis Weeks,Thomas Bruderer,Reno Frei,Timothy R. WalshFirst Report of the Metallo-β-lactamase SPM-1, in Europe. Antimicrobial agents and chemotherapy. Jan 2010; 54(1):582.
49.Fahd Manzoor, Thokar Manzoor Ahmed,Shamweel Ahmed.Extended spectrum-β-Lactamase (ESBL) producing community acquired Escherichia coli isolates & their antimicrobial susceptibility pattern in Kashmir. Journal of pharmaceutical and biomedical Sciences (JPBMS).2012;15(01)1.Available online at www.jpbms.info.
50.Peer Maroof Ahmad, Manzoor A. Thokar,Bashir A.Fomda, Kaiser A. Extended spectrum-β-Lactamase producing Klebsiella pneumonia at a tertiary care setup in Kashmir, India: Comparative phenotypic detection and antimicrobial susceptibility pattern. Reviews in Infection. 2010;1(2):124-130.
51.Ahmed K, Thokar M.A, Toboli A.S, Fomda B.A, Bashir, G, Maroof P. Extended spectrum -Beta-lactamase mediated resistance in Escherichia coli in a tertiary care hospital in Kashmir,India.African Journal of Microbiology Research.2010;4(24):2720-2728.
52.Bashir Deeba, Thokar MA, Fomda BA, et al. Detection of metallo-β-lactamase (MBL) producing Pseudomonas aeruginosa at a tertiary care hospital in Kashmir. African Journal of Microbiology Research. 2011;5(2):164–172.
53.Dar JA, Thoker MA, Khan JA, Ali A, Khan MA, Rizwan M, Bhat KH, Dar MJ, Ahmed N, Ahmad S.Molecular epidemiology of clinical and carrier strains of methicillin resistant Staphylococcus aureus (MRSA) in the hospital settings of north India. Ann Clin Microbiol Antimicrob. 2006 Sep 14; 5:22.
54.Rasmussen, B. A., and K. Bush. 1997. Carbapenem-hydrolyzing β-lactamases. Antimicrob. Agents Chemother.41:223-232.
55.McManus-Munoz, S., and M. W. Crowder. 1999. Kinetic mechanism of metallo-β-lactamase L1 from Stenotrophomonas maltophilia. Biochemistry 38:1547-1553
56.Spencer, J., A. R. Clarke, and T. R. Walsh. 2001. Novel mechanism of hydrolysis of therapeutic β-lactams by Stenotrophomonas maltophilia L1 metallo-β-lactamase. J. Biol. Chem. 276:33638-33644.
57.Wang, Z., W. Fast, and S. J. Benkovic. Direct observation of an enzyme-bound intermediate in the catalytic cycle of the metallo-β-lactamase from Bacteroides fragilis. J. Am. Chem. Soc. 1998; 120:10788-10789.
58.Page, M. I.1999. The reactivity of β-lactams, the mechanism of catalysis and the inhibition of β-lactamases. Curr. Pharm. Des. 5:895-913.
Medline
59.Page, M. I. Understanding metallo-β-lactamases. ASM News. 2002;68:217-221.
60.Arakawa Y, Shibata N, Shibayama K, Kurokawa H, Yagi T, Fujiwara H, Goto M. Convenient test for screening metallo-beta-lactamase-producing gram-negative bacteria by using thiol compounds. J Clin Microbiol. 2000 Jan;38(1):40-3.
61.Lee K, Chong Y, Shin HB, Kim YA, Yong D, Yum JH. Modified Hodge and EDTA-disk synergy tests to screen metallo-beta-lactamase-producing strains of Pseudomonas and Acinetobacter species. Clin Microbiol Infect. 2001 Feb;7(2):88-91.
62.Yong D, Lee K, Yum JH, Shin HB, Rossolini GM, Chong Y. Imipenem-EDTA disk method for differentiation of metallo-beta-lactamase-producing clinical isolates of Pseudomonas spp. and Acinetobacter spp. J Clin Microbiol. 2002 Oct;40(10):3798-801.
63.Michael Smith. ICAAC: New MDR Gene Found in North America. http://www.medpagetoday.com/MeetingCoverage/ICAAC/22154.Published: Sep 13, 2010.
64.Vardakas KZ, Tansarli GS, Rafailidis PI, Falagas ME. Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum beta-lactamases: a systematic review and meta-analysis. J Antimicrob Chemother. 2012;67:2793–803. [PubMed: 22915465].
65.Yong D, Toleman MA, Giske CG, Cho HS, Sundman K, Lee K, et al. Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother. 2009;53:5046–54. [PMCID: PMC2786356] [PubMed: 19770275])
66.Walsh TR, Weeks J, Livermore DM, Toleman MA. Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study. Lancet Infect Dis. 2011; 11:355–62 [PubMed: 21478057] .
67.Travel for Surgery May Help Spread New Superbug. Last Updated: 2010-Aug-11: (Health Day)By-Randy Dotinga. http://www.lahey.org/ Departments_and_Locations/Departments/Ophthalmology/Ebsco_Content/Macular_degeneration.aspx?chunkiid=617377.
68.New antibiotic-resistant bacteria discovery, 07 April 2011, News Centre, Cardiff University, http://www.cardiff.ac.uk/news/articles/new-antibiotic-resistant-bacteria-discovery-6621.html, 16 May 2011.
69.Kusradze I, Diene SM, Goderdzishvili M, Rolain JM. Molecular detection of OXA carbapenemase genes in multidrug-resistant Acinetobacter baumannii isolates from Iraq and Georgia. Int J Antimicrob Agents. 2011;38:164–8. [PubMed: 21616644]
70.Nordmann P, Poirel L, Toleman MA, Walsh TR. Does broad-spectrum beta-lactam resistance due to NDM-1 herald the end of the antibiotic era for treatment of infections caused by Gram-negative bacteria? J Antimicrob Chemother. 2011;66:689–92. [PubMed: 21393184]
71.Walsh TR, Toleman MA. The new medical challenge: why NDM-1? Why Indian? Expert Rev Anti Infect Ther. 2011;9:137–41. [PubMed: 21342058]
72.Sinha K. Lancet says sorry for ‘Delhi bug’ [accessed on August 25, 2011]. Available from: http://timesofindia.indiatimes.com/india/Lancet-says-sorryfor-Delhi-bug-/articleshow/7261135.cms.
73.Detection of Enterobacteriaceae isolates carrying metallobeta- lactamase - United States, 2010. MMWR Morb Mortal Wkly Rep. 2010;59:750. MMWR Morb Mortal Wkly Rep 2010; 59 : 750. [PubMed: 20577157]
74.Kus JV, Tadros M, Simor A, Low DE, McGeer AJ, Willey BM, et al. New Delhi metallo-ss-lactamase-1: local acquisition in Ontario, Canada, and challenges in detection. CMAJ. 2011;183:1257–61. [PMCID: PMC3153514] [PubMed: 21624908].
75.Jovcic B, Lepsanovic Z, Suljagic V, Rackov G, Begovic J, Topisirovic L, et al. Emergence of NDM-1 metallo-beta-lactamase in Pseudomonas aeruginosa clinical isolates from Serbia. Antimicrob Agents Chemother. 2011;55:3929–31.[PMCID: PMC3147624] [PubMed: 21646490].
76.Kusradze I, Diene SM, Goderdzishvili M, Rolain JM. Molecular detection of OXA carbapenemase genes in multidrug-resistant Acinetobacter baumannii isolates from Iraq and Georgia. Int J Antimicrob Agents. 2011;38:164–8. [PubMed: 21616644].
77. D’Andrea MM, Venturelli C, Giani T, Arena F, Conte V, Bresciani P, et al. Persistent carriage and infection by multiresistant Escherichia coli ST405 producing the NDM-1 carbapenemase: a report on the first Italian cases. J Clin Microbiol. 2011;49:2755–8. [PMCID: PMC3147842] [PubMed: 21525229].
78.Kahan, F. M., H. Kropp, J. G. Sundelof, and J. Birnbaum. Thienamycin: development of imipenem-cilastatin. Antimicrob. Agents Chemother. 1983; 12(Suppl. D):S1-S35.
79.Lim, H. M., J. J. Pene, and R. W. Shaw. Cloning, nucleotide sequence, and expression of the Bacillus cereus 5/B/6 β-lactamase II structural gene. J. Bacteriol. 1988;170:2873-2878.
80.Massidda, O., G. M. Rossolini, and G. Satta. 1991. The Aeromonas hydrophila cphA gene: molecular heterogeneity among class B metallo-β-lactamases. J. Bacteriol. 173:4611-4617.
81. Sabath LD, Abraham EP. Zinc as a cofactor for cephalosporinase from Bacillus cereus 569. Biochem J. 1966; 98 : 11C-3.
81.Shannon K, King A, Phillips I. Beta-lactamases with high activity against imipenem and Sch 34343 from Aeromonas hydrophila. J Antimicrob Chemother 1986; 17:45-50.
82. Cuchural GJ Jr, Malamy MH, Tally FP. Beta-lactamase mediated imipenem resistance in Bacteroids fragilis. Antimicrob Agents Chemother 1986; 30 : 645-8.
83. Quiroga, M. I., N. Franceschini, G. M. Rossolini, G. Gutkind, G. Bonfiglio, L. Franchino, and G. Amicosante. 2000. Interaction of cefotetan and the metallo-β-lactamases produced in Aeromonas spp. and in vitro activity. Chemotherapy 46:177-183.
84.Wang, Z., W. Fast, A. M. Valentine, and S. J. Benkovic. 1999. Metallo-β-lactamase: structure and mechanism. Curr. Opin. Chem. Biol. 3:614-622.
85.Chu, Y.-W., M. Afzal-Shah, E. T. S. Houang, M.-F. I. Palepou, D. J. Lyon, N. Woodford, and D. M. Livermore. 2001. IMP-4, a novel metallo-β-lactamase from nosocomial Acinetobacter spp. collected in Hong Kong between 1994 and 1998. Antimicrob. Agents Chemother. 45:710-71.
86. Iyobe, S., H. Kusadokoro, J. Ozaki, N. Matsumura, S. Minami, S. Haruta, T. Sawai, and K. O'Hara. 2000. Amino acid substitution in a variant of IMP-1 metallo-β-lactamase. Antimicrob. Agents Chemother. 44:2023-2027.
87.Livermore, D. M., and N. Woodford. 2000. Carbapenemases: a problem in waiting? Curr. Opin. Microbiol. 3:489-495.
88.Mehul S Chaudhari,et al. A Study of metallo-beta-lactatamase producing pseudomonas aeruginosa in clinical samples OF S.S.G. HOSPITAL. National journal of medical research. Oct–Dec 2011;1(2):60-61.
89. Lee K, YumJH, Jong D, et al. A novel acquired metallo-b-lactamase gene, blaSIM-1, in a class 1 integron from Acinetobacter baumannii clinical isolates from Korea. Antimicrob Agents Chemother (in press).
90.Gales, A. C., L. C. Menezes, S. Silbert, and H. S. Sader. 2003. Dissemination in distinct Brazilian regions of an epidemic carbapenem-resistant Pseudomonas aeruginosa producing SPM metallo-β-lactamase. J. Antimicrob. Chemother. 52:699-702.
91.Lee, K., W. G. Lee, Y. Uh, G. Y. Ha, J. Cho, and Y. Chong. 2003. VIM- and IMP-type metallo-β-lactamase-producing Pseudomonas spp. and Acinetobacter spp. in Korean hospitals. Emerg. Infect. Dis. 9:868-871.
92.Arakawa, Y., M. Murakami, K. Suzuki, H. Ito, R. Wacharotayankun, S. Ohsuka, N. Kato, and M. Ohta.. A novel integron-like element carrying the metallo-β-lactamase gene blaIMP. Antimicrob. Agents Chemother. 1995;39:1612-1615.
93.Lauretti, L., M. L. Riccio, A. Mazzariol, G. Cornaglia, G. Amicosante, R. Fontana, and G. M. Rossolini. 1999. Cloning and characterization of blaVIM, a new integron-borne metallo-β-lactamase gene from a Pseudomonas aeruginosa clinical isolate. Antimicrob. Agents Chemother. 43:1584-1590.
94.Mendes, R. E., M. A. Toleman, J. Ribeiro, H. S. Sader, R. N. Jones, and T. R. Walsh. Genetic characterization of a novel metallo-β-lactamase gene, blaIMP-16: a highly divergent blaIMP with a unique genetic context. Report from the SENTRY Antimicrobial Surveillance Program. Antimicrob. Agents Chemother. 2004; 48:4654-4661.
Article citation:
Idris N,Mohamed FEH,Thokar MA. Rationalizing antibiotic usage in Multidrug resistant Mbl (Metallo ß lactamase)producing Pseudomonas aeruginosa infections. J Pharm Biomed Sci 2014; 04(05):382-394. Available at www.jpbms.info.
Source of support: None
Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Copyright © 2014. Idris N,Mohamed FEH,Thokar MA. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Original Article
P. Jhanwar 1,*, Harish Kumar Jain1, Suresh Dhakar2, Anshul Jhanwar3
Affiliation:-
1Associate Professor, 2Senior Resident, 3Demonstrator, Jhalawar Medical College, Jhalawar (Rajasthan),India
The name of the department(s) and institution(s) to which the work should be attributed:
Department of Orthopaedics, Jhalawar Medical College, Jhalawar (Rajasthan) India
*To whom it corresponds:-
Dr. P. Jhanwar;
Department of Orthopaedics, Jhalawar Medical College, Jhalawar (Rajasthan) India
Abstract
Purpose: To assess the results of minimal internal and hybrid external fixation for the management of a tibial plateau fracture with compromised soft tissue.
Methods: Total 17 cases of tibial plateau fracture with compromised soft tissue underwent minimal internal and hybrid external fixation between June 09 to June 12 in orthopedic department of S.R.G. Hospital & Medical College,Jhalawar (Rajasthan),India after a minimum of 12 months of follow-up (range 12–24 months) each affected knee was evaluated using Rasmussen’s radiological and functional scoring system.
Results: Fourteen procedures involved the right and three procedures involved the left knee. Five procedures were open and twelve were closed injuries with compromised soft tissue and skin blisters. Twelve cases of tibial plateau fractures were Schatzker type I, II & III, 2 were type IV and three type V & VI. Complications consisted of 2 pin site infections and 2 superficial infections. Soft tissue necrosis and proximal tibial bone exposure occurred in one patient, who was managed with split skin grafting. The mean Rasmussen radiological score was 12.62(range, 4–18).This score was excellent in 5 cases, good in 9 cases, fair in 1 and poor in 2 cases. The mean Rasmusssen functional score was 26.22(range, 9–30). This score was excellent in 10 patients, good in 4 patients, fair in 2 patients, and poor in 1 patient. Functional results were not parallel to radiological results. Fourteen patients (82.35%) had acceptable functional results (sum of excellent and good results).
Conclusion: Minimal internal and hybrid external fixation for management of a tibial plateau fracture is more biological, requires less surgical and hospital stay time, can be done in the presence of compromised soft tissue, is cost effective, and has minimal complications and good functional outcomes.
Keywords: External fixator; tibial plateau fractures; hybrid fixator.
REFERENCES
1.Watson JT. High-energy fractures of the tibial plateau. Orthop Clin North Am 1994; 25:723–52.
2.ColePA,ZlowodzkiM,KregorPJ.Treatment of proximal tibia fractures using the less invasive stabilization system:surgical experience and early clinical results in 77 fractures.J orthop Trauma.2004;18:52835.
3.MillsWJ,NorkSE.Open reduction and internal fixation of high-energy tibial plateau fractures. Orthop
Clin North Am 2002; 33:177–98.
4.Sirkin MS,Bono CM,Reilly MC,Behrens FF. Percutaneous methods of tibial plateau fixation. Clin Orthop Relat Res 2000;375:608.
5.Piper KJ, Won HY, Ellis AM. Hybrid external fixation in complex tibial plateau and plafond fractures:an Australian audit of outcomes. Injury 2005;36:178–84.
6.Schatzker J,McBroom R,Bruce D.The tibial plateau fracture.The Toronto experience 1968-1975.Clin Orthop Relat Res 1979;138:94–104.
7.Oestern HJ,Tscherne H. Pathophysiology and classification of soft tissue damage in fractures [in German]. Orthopade 1983;12:28.
8.Rasmussen PS. Tibial condylar fractures. Impairment of knee joint stability as an indication for surgical treatment. J Bone Joint Surg Am 1973;55:1331–50.
9.DeCosterTA,NepolaJV,el-KhouryGY.Castbrace treatment of proximal tibia fractures.A ten- year follow-up study.Clin
10.Moore TM, Patzakis MJ, Harvey JP. Tibial plateau fractures: definition, demographics, treatment rationale, and long-term results of closed traction management or operative reduction. J Orthop Trauma 1987;1:97–119.
11.Young MJ, Barrack RL. Complications of internal fixation of tibial plateau fractures. Orthop Rev 1994;23:14954.
12.Christensen K,Powell J,Buchol zR,StillsM.Early results of combined internal-external fixation for treatment of high-grade tibial plateau fractures. J Orthop Trauma 1990;4:226.13.RangitschMR,DuweliusPJ,ColvilleMR.Limited internal fixation of tibial plateau fractures:a prospective protocol. J Orthop Trauma 1993; 7:168–9.
14.Salter RB, Simmonds DF, Malcolm BW, Rumble EJ, MacMichael D, Clements ND. The biological effect of continuous passive motion on the healing of full-thickness defects in articular cartilage.An experimental investigation in the rabbit. J Bone Joint Surg Am 1980;62:1232–51.
15.StannardJP, Wilson TC, VolgasDA, Alonso JE. The less invasive stabilization system in the treatment of complex fractures of the tibial plateau: short-term results. J OrthopTrauma2004;18:552–8.
16.Golyakhovsky V, Ferrara PL. Operative manual of Ilizarov techniques. Mosby; 1993:171–90.
17.WatsonJT,RippleS,HoshawSJ,FhyrieD.Hybrid external fixation for tibial plateau fractures:clinical and biomechanical correlation. Orthop Clin North Am 2002;33:199–209.
18.LachiewiczPF,FuncikT.Factors influencing the results of open reduction and internal fixation of tibial plateau fracture.
Source of support: None
Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Article citation:
Jhanwar P, Jain HK, Dhakar S, Jhanwar A. Management of a tibial plateau fracture with compromised soft tissue using minimal internal and hybrid external fixation. J Pharm Biomed Sci 2014;04(05):427-433.Available at www.jpbms.info.
Copyright © 2014 Jhanwar P, Jain HK, Dhakar S, Jhanwar A. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.